Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

After median follow-up was 21.9 months, the IMvigor010 trial did not meet its primary endpoint of improved disease-free survival with atezolizumab vs observation (n=809; median disease-free survival 19.4 vs 16.6 months; HR 0.89; 95% CI 0.74–1.08; p=0.24).

Source:

The Lancet Oncology